An orthobiologic treatment for osteoarthritis based on autologous cartilage micrografts, designed to modulate inflammation, support joint regeneration and pain management through a minimally invasive procedure.
Request Clinical Information Watch Procedure Video
Derived entirely from the patient's own cartilage — zero risk of rejection or immune response.
Only a small biopsy taken from the ear. No surgical incision. No general anesthesia required.
Patients can resume normal daily activity shortly after the procedure with minimal restrictions.
The entire procedure fits comfortably within a standard clinical consultation session.
Mytocel MSK uses Autologous Micrografting Technology (AMT®) to convert a small auricular cartilage sample into a tissue-specific suspension ready to inject.
Prepared during the same clinical session, Mytocel MSK delivers biologically active components directly to the target joint.
Autologous Point-of-Care Minimally Invasive 
The micrograft suspension contains all the components from the “diamond of regeneration” – Creating a unique regenerative micro-environment within the affected Osteoarthritis joint.
Chondroblasts that can differentiate into chondrocytes and communicate with the local cells from the hyaline cartilage.
An organized net of collagen, elastin and hyaluronic acid that mantains a specific niche that improves the cell’s function.
Chemical messengers that promote the immunomodulation of the joint.
Which help promote the regeneration of the cartilage and enable the paracrine communication between cells.
Peer-reviewed publications, clinical studies and real-world evidence demonstrating the potential of Mytocel MSK in musculoskeletal regeneration.
Gabriele Ceccarelli, Pietro Gentile, Marco Marcarelli, Martina Balli, Flavio Lorenzo Ronzoni, Laura Benedetti and Maria Gabriella Cusella De Angelis
Learn MoreCamilo Partezani Helito, Valeria Pessei, Cecilia Zaniboni and Ilie Muntean
Learn MoreDimitrios Tsoukas, Ilie Muntean, Christos Simos, Ruben Sabido-Vera
Learn MoreThe Mytocel MSK Procedure
A point-of-care procedure designed to prepare autologous cartilage micrografts for application to the affected joint.
for application to the affected joint.
Autologous cartilage is mechanically disaggregated using Mytocel technology to obtain a micrograft suspension.
The resulting autologous micrograft suspension is applied to the affected joint within the same clinical session.
Access detailed clinical information and hands-on training for healthcare professionals.
Clinical Conditions
Grade I-III OA
Cartilage Injuries
Tendinopathies
Chondromalacia Patellae
Knee
Hip
Shoulder
Ankle
Thumb
Clinical Comparison
A science-based comparison of the leading injectable orthobiologic options for osteoarthritis.
| Characteristics | Mytocel MSK AMT® | MACI/ACI | BMAC | ATMSCs | PRP & Blood derived products | HA |
|---|---|---|---|---|---|---|
| Autologous Source |
|
|
|
|
|
|
| Viable cells |
|
|
|
|
|
|
| Tissue – specific |
|
|
|
|
|
|
| Typology | Ambulatory | Surgery room | Ambulatory | Ambulatory/surgery room | Ambulatory | Ambulatory |
| Time | 30 min | 2-4 hours | 4-6 hours | 2-4 hours | 30 min | 30 min |
| Posology | 1 session | 1 session | 1 session | 1 session | 3-4 sessions | Every 6 months |
| Indication | OA, tendinopathy, cartilage damage | Cartilage lesions bigger than 2 cm | Intrarticular OA, OA, tendinopathy, muscular damage, bone remodelling | Intrarticular OA, OA, tendinopathy, muscular damage, bone remodelling | Intrarticular OA, OA, tendinopathy, cartilage damage | OA, tendinopathy |
Voices from leading orthopaedic surgeons and researchers who have worked with Mytocel MSK.
Degenerative joint disease is not only a cartilage problem — it is a disruption of the entire joint microenvironment. Autologous micrografting offers a biological approach to restoring that balance.
One of the most interesting aspects of autologous micrografting is the ability to obtain biologically active tissue directly at the point of care within the same clinical session.
Autologous micrografting can be prepared during the same clinical session to deliver biologically active components directly to the target joint, supporting regeneration and pain management.
Stay updated with upcoming webinars, congress participation and training sessions related to Mytocel MSK.